Comparing Piperacillin Tazobactam and Meropenem for Bloodstream Infections Caused by Cephalosporin-Resistant Enterobacteriaceae
A Phase 4 Randomized Trial to Test Treatment Effectiveness
Led by Rambam Health Care Campus · Updated on 2025-08-01
1084
Participants Needed
14
Research Sites
12 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the best treatment for bloodstream infections caused by cephalosporin-resistant Enterobacteriaceae bacteria, specifically looking at whether piperacillin-tazobactam is as effective as meropenem. The study focuses on adults with blood infections due to E. coli or Klebsiella species that are resistant to certain antibiotics but susceptible to both study drugs. The trial aims to determine if piperacillin-tazobactam is not worse than meropenem in treating these infections.
Participants are randomly assigned to receive either piperacillintazobactam at a dose of 4.5 grams four times a day or meropenem at 1 gram three times a day. Both treatments are given to treat the bloodstream infection during the study. The trial includes patients with both community and hospital-acquired infections and excludes those with certain severe conditions or prior infections not fully treated.
During the study, participants are monitored for outcomes such as death within 30 days and treatment failure within 7 days after starting treatment. Additional assessments include mortality at 14 and 90 days, microbiological outcomes, infection relapses, hospital readmissions, antibiotic use, resistance development, and adverse events. The study collects detailed data over 90 days to evaluate the safety and impact of these antibiotic treatments.
CONDITIONS
Brief Title
PipEracillin Tazobactam Versus mERoPENem for Treatment of Bloodstream Infections Caused by Cephalosporin-resistant Enterobacteriaceae (PETERPEN)
Research Team
M
Mical Paul, MD
R
Roni Bitterman, MD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
New bloodstream infection caused by E. coli or Klebsiella species confirmed in one or more blood cultures with evidence of infection
Infection resistant to third generation cephalosporins but susceptible to both piperacillin-tazobactam and meropenem
Includes both community-acquired and hospital-acquired bloodstream infections
Allows inclusion if blood cultures show skin bacteria considered contaminants along with primary infection
You will not qualify if you...
More than 72 hours have passed since the initial blood culture was taken
Presence of polymicrobial bacteremia with two or more different species in the same or separate blood cultures
Previous bacteremia or infection not fully treated with antimicrobial therapy
Septic shock at enrollment, defined by low blood pressure or use of vasopressor medications
Bloodstream infections known at enrollment such as endocarditis, osteomyelitis (unless removed), or central nervous system infections
Allergy to either study drug
Previous enrollment in this trial
Participation in another interventional clinical trial
Expected death within 48 hours of recruitment according to researcher assessment
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Treatment
Duration - Up to 30 days from randomization
Participants receive either piperacillin/tazobactam or meropenem as treatment for bloodstream infection caused by cephalosporin-resistant Enterobacteriaceae.
Visits as required during treatment period
Follow-up
Duration - Up to 90 days from randomization
Participants are monitored for treatment outcomes and any adverse events after completion of treatment.
Follow-up visits to assess health status and infection recurrence
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Similar Trials
Evaluating Aztreonam-Avibactam for Resistant Bacterial Infections in Adults with Weakened Immune Systems An International Observational Study Comparing Treatment Outcomes
Comparing Beta-lactam Alone Versus Beta-lactam Plus Levofloxacin for Treating Streptococcal Bacteremia in Adults
Comparing Echocardiography to No Echocardiography in Adults with Staphylococcus Aureus Bloodstream Infection and Low VIRSTA Score
Assessment of the Diagnostic Accuracy and Performance of the UllCORE Bloodstream Infection Test in Patients with Suspected Sepsis or Bloodstream Infection
Study of a New Guideline for Managing Febrile Infants Up to 60 Days Old
Comparing Current Practices in Swedish Pediatric Emergency Departments
Phase III Study of Capsule-Delivered Fecal Microbiota Transplantation to Remove Drug-Resistant Gram Negative Bacteria Carriage
Randomized Trial of Fecal Microbiota Transplantation to Remove Carbapenem-resistant Enterobacteriaceae from the Gut
Study of Fecal Microbiota Transplantation to Remove Intestinal Carbapenem-resistant Enterobacteriaceae in Adults
International Study to Observe Safety and Outcomes of Intravenous Fosfomycin in Adults with Severe Bacterial Infections
Evaluating Blood Cultures From Arterial Lines Versus Peripheral Veins to Detect Bacteremia and Contamination in Intensive Care Patients An Observational Study
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
Piperacillin-tazobactam versus meropenem for treatment of bloodstream infections caused by third-generation cephalosporin-resistant Enterobacteriaceae: a study protocol for a non-inferiority open-label randomised controlled trial (PeterPen).